- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Orchid Pharma's board approved its Q3 and nine-month financial results. Consolidated Net Sales reached ₹207.27 Cr, reporting a net loss of ₹12.61 Cr for the quarter. EPS was (₹2.49). An exceptional ₹7.11 Cr liability from new Labour Codes was noted. QIP funds of ₹391.80 Cr are mostly utilized. Amalgamation talks continue. #OrchidPharma #Q3FY26